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Clinical outcomes for patients with a wide range of malignancies have improved substantially over 
the last two decades. Tyrosine kinase inhibitors (TKI) are potent signalling cascade inhibitors and 
have been responsible for significant advances in cancer therapy. By inhibiting vascular endothelial 
growth factor receptor- (VEGFR-) mediated tumour blood vessel growth, VEGFR-TKIs have become 
a mainstay of treatment for a number of solid malignancies. However, the incidence of VEGFR-TKI-
associated cardiovascular toxicity is substantial and previously under-recognised. Almost all patients 
have an acute rise in blood pressure and the majority develop hypertension. They are associated with 
the development of left ventricular systolic dysfunction (LVSD), heart failure and, myocardial 
ischaemia and can have effects upon myocardial repolarisation. Consideration should be given to 
rigorous baseline assessment of patients prior to commencing VEGFR-TKIs, with careful attention 
paid to baseline cardiovascular risk factors. Baseline blood pressure measurement, electrocardiogram, 
and cardiac imaging should be performed routinely. Hypertension management currently follows 
national guidelines but there may be a future role for ET-1 antagonism in the prevention or treatment 
of VEGFR-TKI-associated hypertension. VEGFR-TKI-associated LVSD appears to be independent 
of dose and is reversible. Patients who develop LVSD and heart failure should be managed with 
conventional heart failure therapies but the role of prophylactic therapy is yet to be defined. Serial 
monitoring of left ventricular function and QT interval require better standardisation and co-ordinated 
care. Management of these complex patients requires collaborative, cardio-oncology care to allow the 
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Over the last two decades, clinical outcomes for patients with cancer have improved substantially. 
Approximately 50% of patients who develop cancer in any form will survive at least 10 years. [1]   
Tyrosine kinase inhibitors (TKIs) have accounted for a proportion of this success and these small 
molecule drugs have been developed to act against several primary signalling targets including 
epidermal growth factor, platelet-derived growth factor and breakpoint cluster region-Abelson murine 
leukaemia (Bcr-Abl).  Vascular endothelial growth factor receptor- (VEGFR-)TKIs represent a major 
advance in the management of patients with a wide range of malignancies (Figure 1, Tables 1 and 2) 
and will form the basis of this review. This oncological success has been accompanied by new 
challenges, including the management of VEGFR-TKI-associated adverse cardiovascular effects. 
VEGFR-TKIs cause hypertension, left ventricular systolic dysfunction/heart failure, atherothrombosis 
and can also cause QT interval prolongation and dysrhythmia (Figure 2) [2], [3].  It is important to 
note that cardiovascular toxicity profiles of VEGFR-TKIs differ from those associated with TKIs 
directed primarily against other, non-VEGF, signal-transduction pathways.  
Although potential for cardiovascular toxicity was identified early in drug development, rigorous 
patient selection in pivotal trials may have led to underestimation of the true impact in routine clinical 
practice. Additionally, no trials document long term safety follow-up despite some patients remaining 
on treatment for several years and potentially surviving several more. Therefore, it is likely that latent 
cardiovascular toxicity and that associated with chronic exposure have been under-reported. Some 
patients will have had previous chemotherapy or radiotherapy that can lower the threshold for 
subsequent VEGFR-TKI-associated cardiotoxicity [4]. The aim of providing high quality 
cardiovascular management should be to allow patients to continue safely receiving optimal doses of 
VEGFR-TKI therapy, minimising treatment interruption or dose reduction. 
  
VEGF Signalling and Its Inhibition  
Tumour growth is critically dependent upon a sufficient blood supply. As a solid tumour grows, the 
central core becomes hypoxic stimulating physiological tissue growth and repair pathways, including 
the release of angiogenic growth factors to allow new blood vessel formation (neo-angiogenesis). The 
VEGF pathway is central to this process and its inhibition has therefore become a major therapeutic 
target in cancer therapy. VEGF has multiple isoforms and binds to three tyrosine kinase receptors. It 
plays a pivotal role in endothelial cell proliferation and survival, vascular permeability, and 
angiogenesis by binding to VEGFR-2. [5]  
 
In addition to their VEGF signalling effects, VEGFR-TKIs also inhibit a variable number of other 
tyrosine kinase targets.  This broadens their therapeutic effects against an expanding range of 
malignancies but may also contribute to their adverse cardiovascular effects (Table 2). [6]  
 
HYPERTENSION 
Hypertension is a class effect of VEGFR-TKI therapy and is the most common manifestation of 
cardiovascular toxicity. Almost every trial reports a treatment-associated rise in blood pressure (BP) 
and up to 80% of patients develop hypertension, either de novo or worsening of previously controlled 
high BP. [7] Registry data reveal that 73% of patients receiving targeted therapy (primarily VEGFR-
TKIs) for renal cell cancer (RCC), developed cardiovascular toxicity, 55% of which was accounted 
for by hypertension. [8] VEGFR-TKI-associated hypertension can be severe and difficult to treat [7]–
[9] but it is dose-dependent and reversible on discontinuing the VEGFR-TKI. 
 
Clinical Consequences of VEGFR-TKI-Associated Hypertension 
An acute rise in BP in patients not previously ‘conditioned’ to the effects of hypertension can 
precipitate acute end-organ complications, such as stroke, myocardial ischaemia, heart failure and 
acute kidney injury at a lower threshold than might be expected in patients with long-standing 
hypertension. [10] This is relevant as VEGFR-TKI-associated hypertension, develops within hours to 
days of starting therapy. Therefore, prior to introducing a VEGFR-TKI, a comprehensive assessment 
for pre-existing cardiovascular disease is important and management of pre-existing hypertension 
optimised.   Early recognition of VEGFR-TKI-associated hypertension and prompt initiation of 
treatment remains fundamental. The development of VEGFR-TKI-associated hypertension is 
associated with better cancer outcomes but, importantly, anti-hypertensive treatment does not modify 
the anti-cancer effect. [11] 
 
Although rare (<1% of patients), VEGFR-TKIs have been associated with the development of 
posterior reversible leucoencephalopathy. [12], [13]This presents with headache, confusion, seizures 
and visual impairment. Magnetic resonance imaging of the brain reveals characteristic posterior fossa 
changes on T2-weighted imaging reflecting oedema. The underlying pathophysiology seems to be 
related to the combination of hypertension, impaired cerebral auto-regulation and cerebrovascular 
permeability/endothelial dysfunction. Importantly, if this condition is diagnosed early, hypertension 
treated promptly and VEGFR-TKI withdrawn, there is a favourable prognosis. 
 
As patients survive longer and receive VEGFR-TKIs for prolonged periods, the chronic end-organ 
effects of hypertension need careful consideration. However, long-term follow-up data are lacking.   
 
 
Mechanism of VEGFR-TKI-Associated Hypertension 
Mechanisms underlying the development of hypertension during VEGFR-TKI therapy remain 
incompletely defined. The acute increase in BP upon VEGFR-TKI treatment, and its reduction upon 
VEGFR-TKI cessation, [14] suggest that changes in vascular tone are of fundamental importance. 
Rarefaction, a reduction in capillary density, is also notable [15] but whether this is a cause or a 
consequence of VEGFR-TKI-associated hypertension remains unclear.  
 
Reduced nitric oxide (NO) bioavailability is a potentially important factor in VEGFR-TKI-associated 
hypertension. VEGF stimulates NO release, while VEGF inhibition is associated with decreased NO 
generation. In patients treated with VEGFR-TKI, plasma levels of nitrate and its metabolites are 
reduced, but return to baseline following withdrawal of treatment. [16] VEGFR-TKI therapy is also 
associated with increased production of potent vasoconstrictor, endothelin-1 (ET-1). [14] Pre-clinical 
data in swine demonstrate the effective reversal of acute VEGFR-TKI-associated hypertension by ET-
1 receptor antagonism.[17] There may, therefore, be a role for ET-1 receptor antagonists in the 
treatment, or prevention, of VEGFR-TKI-related hypertension. However, this has yet to be proven 
clinically. Recent studies have identified oxidative stress as another mechanism for VEGFR-TKI-
induced vascular dysfunction in hypertension. [18]  
 
While the renin-angiotensin-aldosterone (RAA) system is critically implicated in the pathophysiology 
of essential hypertension, there is no convincing evidence that it plays a major role in VEGFR-TKI-
associated hypertension. [19] VEGFR-TKI therapy is associated with decreased renin activity in 
experimental models [16], [20] and angiotensin-converting enzyme (ACE) inhibition has a limited 
impact on VEGFR-TKI-related hypertension when compared with calcium-channel antagonism in 
these models. [21] Consistent with these pre-clinical findings, patients treated with sunitinib had a rise 
in BP of around 15mmHg but with a 60% decrease in plasma renin and no change in aldosterone 
levels [22] which may reflect a secondary down-regulation of the RAA system. [20], [21] 
 
Assessment and Treatment of VEGFR-TKI-Associated Hypertension 
The Cardiovascular Toxicities Panel of the National Cancer Institute provide guidance on the 
assessment and management of VEGFR-TKI-associated hypertension [23] which is also highlighted 
in a European Society of Cardiology position paper. [3] BP should be monitored by the oncology 
team frequently (weekly during the first cycle) and subsequently 2- to 3-weekly. Home BP monitoring 
has been recommended during treatment but this may not always be feasible. [24]  
 Patients with a BP of ≥140/90 mmHg should receive anti-hypertensive treatment. [24], [25] Choice of 
anti-hypertensive agents generally follows national guidelines for first-line treatment of hypertension 
and there is currently no clinical evidence of superiority of one agent over another (Table 3). [26] 
However, non-dihydropyridine calcium channel antagonists such as verapamil and diltiazem inhibit 
cytochrome P450 3A4 and should be avoided because of the potential for consequent VEGFR-TKI 
toxicity [3], [11]. ACE inhibitors or angiotensin receptor blockers (ARBs) may be of benefit in 
patients with left ventricular systolic dysfunction (LVSD) or proteinuria induced by VEGFR-TKIs. 
However, given the limited evidence for the RAA system in the pathophysiology of VEGFR-TKI-
associated hypertension, pathophysiologically-targeted treatment is notably absent. Multiple agents 
are frequently required to achieve satisfactory control and although agents such as nebivolol and long-
acting nitrates improve BP control in VEGFR-TKI-associated hypertension, [27] alternative anti-
hypertensives have not been extensively evaluated in this setting (Tables 3 and 4). 
 
Some VEGFR-TKI treatment regimens have off-periods during which VEGFR-TKIs are temporarily 
withheld. For example, sunitinib is conventionally given for 4 weeks followed by a 2-week break 
(Figure 3). During this time, vigilance to possible symptomatic rebound hypotension is important. 
[28] Dose reduction or temporary withdrawal of anti-hypertensive agents may be required. [7]  
 
Prior to commencing treatment with a VEGFR-TKI, referral for cardio-oncology review should be 
considered in patients with a history of hypertension and this is particularly important for patients 
with sub-optimal BP control or hypertension-related end-organ dysfunction. [29] The development of 
VEGFR-TKI-associated hypertension that is not easily controlled with a single agent, or where there 
is evidence of end-organ damage should prompt referral to a cardio-oncologist. However, there 
appears to be wide variation in practice around the globe. Although there are no guidelines 
recommending thresholds for discontinuation of VEGFR-TKI therapy, severe hypertension may 
require dose reduction or withdrawal, but this should generally be considered a last resort. Decision-
making and management requires input from both the oncologist and cardiologist and needs to take 
account of cancer and cardiovascular risks, and whether there is an alternative effective cancer 
therapy that can be used in place of a VEGFR-TKI. 
 
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION 
The spectrum of VEGFR-TKI-associated cardiotoxicity ranges from asymptomatic LVSD, to heart 
failure (HF), cardiogenic shock and death.[30], [31] Obtaining an accurate incidence of LVSD or HF 
with VEGFR-TKI use has been limited and that reported may underestimate the reality. The definition 
and reporting of cardiac toxicity has been inconsistent and, despite more robust definitions of HF and 
better reporting of events in clinical trials, [32] long term follow-up data remain sparse. There is often 
overlap between symptoms that may reflect HF with those that are related to cancer. [30]  
 
Meta-analysis of trials of VEGFR-TKIs including 10,647 patients reveals a combined incidence of 
asymptomatic LVSD and HF of 2.4%. 1.2% developed symptomatic heart failure. Notably, there was 
no apparent difference in risk of cardiotoxicity between relatively specific VEGFR-TKIs (e.g. 
axitinib) and those directed against a broader range of tyrosine kinases (e.g. sunitinib, sorafenib, 
vandetanib and pazopanib) [31]. In a randomised controlled trial comparing pazopanib with sunitinib 
for the treatment of RCC, both agents were associated with a 1% incidence of HF and 9% of patients 
in each group had a ≥15% decline in left ventricular ejection fraction (LVEF) over a median duration 
of 8 months. [33] In the large ASSURE trial of 1599 patients with RCC treated with sunitinib, 
sorafenib or placebo, a reduction in LVEF >15% to a value below the lower limit of normal occurred 
in 1.8% and 1.4% for sunitinib and sorafenib respectively, and in 0.9% receiving placebo over six 
months [34]. 
 
Retrospective data from patients undergoing treatment with a VEGFR-TKI at Stanford University 
revealed a similar incidence of HF and these real world patients were also systematically screened for 
the development of asymptomatic LVSD or rise in brain natriuretic peptide. Of 217 patients treated 
with a VEGFR-TKI, 21.6% developed elevated plasma levels of NT-proBNP (>300 pg/mL or a 100% 
increase from a previously elevated level) and 9.6% had  ≥10% decline in LVEF during treatment. [7]  
 
VEGFR-TKI-associated LVSD is at least partially reversible. In a randomised controlled trial of 
sunitinib versus placebo in the treatment of imatinib-resistant gastro-intestinal stromal tumours 28% 
of patients had a reduction of LVEF by ≥10%. [35] A steady decline in LVEF was observed with each 
of four cycles over a 24-week period. 5 of 6 patients with HF had an improvement in LVEF in 
response to HF therapies. Endomyocardial biopsies from these patients demonstrated mitochondrial 
abnormalities but not apoptosis nor fibrosis, further suggesting a reversible process. [35] More 
recently, 90 patients with RCC receiving sunitinib were followed prospectively with 
echocardiographic and biomarker assessment. 9.7% of patients had a decline in LVEF by ≥10% from 
baseline to a value <50%. Eight of the nine patients who developed cardiotoxicity, did so within the 
first cycle of treatment. Importantly, however, with sunitinib dose reduction and/or the institution of 
anti-hypertensive medication, LV dysfunction was at least partially reversible and non-progressive 
over 33 weeks. [36]  
Pathophysiology of LVSD in patients treated with VEGFR-TKI 
Mechanisms underlying VEGFR-TKI-associated cardiac dysfunction appear to reflect direct 
myocardial toxicity amplified by hypertension. Mitochondrial dysfunction and inhibition of AMP-
kinase may be important. VEGF plays a central role in the myocardial hypertrophic response to 
hypertension and VEGFR-TKIs appear to accelerate the process of decompensation from left 
ventricular hypertrophy to dilatation and HF. [37] These on-target effects of VEGFR-TKIs reflect the 
overlap between tyrosine kinases expressed in both the heart and the tumour. However, VEGFR-TKIs 
act at a range of different pathways and off-target effects occur from their limited selectivity. [38] As 
such, given the variety in range and specificity of tyrosine kinases targeted by individual small 
molecule inhibitors it may be an oversimplification to consider any cardiotoxic action as a class 
effect. [30]  
 
Prophylaxis, Monitoring and Treatment 
Risk factors for the development of VEGFR-TKI-associated LVSD or HF are outlined in Table 4. The 
development of cardiac dysfunction appears to be independent of dose or treatment duration. [39]   
 
The American Society of Echocardiography and European Association of Cardiovascular Imaging 
recommend a baseline echocardiogram, with follow-up at 1 month and every 3 months while on 
VEGFR-TKI therapy. However, they concede that this recommendation is based upon opinion and 
lacks a firm evidence base. [40] There is currently wide variation in local practice, but imaging 
assessment is important for patients at higher baseline risk for LV dysfunction and particularly those 
with other potential cancer treatment options. The early development of cardiotoxicity demonstrated 
with sunitinib suggests that screening should be focused to the early cycles of therapy but the onset of 
cardiotoxicity with other VEGFR-TKIs may differ. A low threshold for imaging assessment of LV 
function is vital in patients with symptoms suggestive of HF, particularly given the potentially 
reversible nature of VEGFR-TKI-associated LVSD. 
 
The role of cardiac biomarkers for the prediction and diagnosis of VEGFR-TKI-associated 
cardiotoxicity remains undefined. Notably, in the prospective assessment of patients receiving 
sunitinib, 18.9% of patients had elevation of high sensitivity troponin or natriuretic peptides but this 
did not correspond to an echocardiographically detectable decline in LVEF [36]. It is unclear whether 
this reflects a true disconnect between LVSD and humoral biomarkers or insufficient sensitivity of 
echocardiography to detect subtle alterations in myocardial function.  
Patients with LVSD at baseline or with risk factors for the development of VEGFR-TKI-associated 
LVSD (Table 4) should be referred for cardiology review prior to commencing VEGFR-TKI. Those 
who develop HF or LVSD while receiving VEGFR-TKI treatment should be seen on an urgent basis 
by a cardiologist, preferentially with cardio-oncology expertise. They should receive conventional 
therapy including a beta blocker, ACE inhibitor/ARB and potentially a mineralocorticoid receptor 
antagonist. The decision to interrupt, postpone or switch VEGFR-TKIs in the face of cardiotoxicity is 
complex and requires careful weighing of potential oncologic benefits against cardiac effects and 
specialist cardio-oncology management is vital. However, the development of VEGFR-TKI-
associated LVSD should prompt the interruption of VEGFR-TKI therapy and introduction of ACE 
inhibitor/ARB and beta blockade (Table 4), although there is a complete lack of evidence to guide 
therapy. For those patients with recovery of left ventricular function, resumption of treatment with 
VEGFR-TKI may be considered. [41] 
 
Patients with significantly impaired LV function at baseline were excluded from most pivotal 
VEGFR-TKI trials and, where feasible, alternative treatment approaches should be considered for 
such patients. There is no evidence to support the routine prophylactic use of therapies such as ACE 
inhibitors or beta blockers. 
 
MYOCARDIAL ISCHEMIA 
Although VEGFR-TKIs are associated with both thrombotic and haemorrhagic complications, the risk 
of thrombotic events predominate. [42], [43] The risk of arterial thrombosis is greater than that of 
venous thrombo-embolism [44], [45] and many trials report an increased incidence of myocardial 
ischaemia and acute coronary syndrome but these are reported inconsistently. The incidence is 
variable and depends upon the underlying cancer and its stage. Meta-analysis reveals an incidence of 
arterial thromboembolic events of 1.4% and 1.7% associated with the use of sorafenib and sunitinib, 
respectively [44]. In a major randomised controlled trial of 903 patients with advanced RCC, 3% of 
patients receiving sorafenib suffered myocardial ischemia or infarction compared with <1% receiving 
placebo. [46]  
 
Treatment and Prevention of Cardiac Ischaemia 
One meta-analysis, primarily of patients treated for RCC, reported an incidence of 16.7% of all-grade 
bleeding with sunitinib and sorafenib. 2.4% of events were considered to be ‘high-grade’. [47] 
However, a more recent meta-analysis of trials including a wider range of underlying malignancies 
suggests that the risk of bleeding is primarily ‘low-grade’ with epistaxis being particularly frequent 
(10.8% in VEGFR-TKI treated patients versus 2.2% in controls). Although 13.4% of high grade 
events were accounted for by cerebral haemorrhage this was not statistically different from control 
patients and the small numbers involved limit major conclusions. Gastrointestinal haemorrhage was 
also not significantly different between VEGFR-TKI-treated patients and controls (2.6% versus 3.6% 
respectively).  The risk of haemorrhagic events varies depending upon the underlying tumour type and 
is increased by the use of combination VEGFR-TKI therapy. [48] 
 
Concerns about VEGFR-TKI-associated bleeding pose a dilemma when considering the use of anti-
platelet agents in the treatment or prevention of ischaemic events. [44] In patients who require 
percutaneous coronary intervention, strategies to allow a shorter period of dual anti-platelet therapy 
should be sought.  There are no data to support the routine use of anti-platelets as an anti-ischaemic 
primary preventative strategy (Table 4).  
 
QT INTERVAL PROLONGATION 
QT prolongation with VEGFR-TKIs is reported but varies widely by individual drugs (Table 5). 
Vandetanib is most associated with this effect, with up to 8% of patients exhibiting a corrected QT 
(QTc) interval duration of >500 ms. [3] Meta-analysis of VEGFR-TKI trials found an incidence of 
4.4% of all-grade QTc prolongation when compared to non-TKI therapy. The incidence of QTc 
>500ms was low, and ventricular arrhythmias and sudden death were scarce. [2] However, the 
incidence is likely to be higher in patients not being treated in a clinical trial and VEGFR-TKI-
associated QTc prolongation, torsades de pointes ventricular arrhythmia and sudden death have been 
reported. [49] The mechanism for QT prolongation, which is also seen with other ATP-mimetic TKIs 
is probably distinct from the VEGFR-targeted effects and may be related to interaction with the 
myocardial human ether-a-go-go related gene (hERG) potassium channels. [50] 
 
Care should be taken to avoid co-prescription of other drugs that may prolong the QT interval and to 
avoid or correct electrolyte abnormalities. A baseline ECG should be performed in all patients due to 
start treatment with a VEGFR-TKI. For patients treated with vandetanib, the package insert 
specifically recommends monitoring of the QT interval at baseline, 2-4 weeks, and 8-12 weeks after 
starting treatment and every 3 months thereafter. [23] Package inserts for other VEGFR-TKIs are less 
proscriptive regarding timing of QT interval assessment but state that this should be assessed 
‘periodically’. [23] 
It is recommended that treatment should be suspended if QTc is >500 ms or increases by >60 ms from 
baseline. The risk of torsades de pointes is substantially greater above these thresholds, and these 




TKIs of the VEGF-receptor signalling pathway have had a major impact in the treatment of a wide 
range of cancers and indications for their use have increased substantially. However, they are 
associated with a range of cardiovascular adverse effects including hypertension, LVSD/HF, 
atherothrombosis and QT interval prolongation. Clinical trial estimates of these effects have been 
variable, partly reflecting inconsistent inclusion and definition of cardiovascular endpoints. 
Furthermore, patients receiving VEGFR-TKIs often have substantially more comorbidity than those 
included in clinical trials, putting them at further risk of adverse effects.  
 
Evidence to guide the best approach in the assessment and treatment of VEGFR-TKI-associated 
cardiovascular effects is limited but rigorous baseline cardiovascular risk assessment remains key, 
with particular focus on blood pressure control. The overarching goal should be to allow the 
continued administration of optimal doses of VEGFR-TKI wherever possible, often with the co-
administration of cardiovascular medicines. Decision-making requires close interaction between the 
oncologist and cardiologist, often via a dedicated cardio-oncology clinic. Such collaborative care 
should be considered as a basic standard to allow patients to achieve the true therapeutic potential 
from cancer treatment whilst minimising competing cardiovascular effects. 
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Category  Examples 
Tyrosine Kinase 
Inhibitors (TKI) 
Umbrella term for all small molecule 
inhibitors, directed against either 
single or multiple tyrosine kinases; 
primary targets include Bcr-Abl, EGFR 
and VEGFR 
Bcr-Abl: imatinib 
               nilotinib  
               dasatinib  
               bosutinib  
               ponatinib 
  EGFR:    gefitinib  
               lapatinib  
               erlotinib  
               afatinib  
               osimertinib 
  VEGFR:  axitinib  
            cabozantinib  
            lenvatinib  
            nintedanib 
            pazopanib 
            regorafenib 
            sorafenib 
            sunitinib 
            tivozanib 
               vandetanib 
Non-TKI VEGF Inhibitors   
       VEGF mAb Monoclonal antibodies targeting 
circulating VEGF 
bevacizumab 
       VEGFR mAb Monoclonal antibodies targeting VEGF 
receptors 
ramirucimab 
       VEGF Trap Mimic VEGF receptors and bind to 
circulating VEGF 
aflibercept 
Table 1. Terms used to describe angiogenesis inhibitors and tyrosine kinase inhibitors. VEGFR – 
Vascular Endothelial Growth Factor Receptor, mAb – Monoclonal antibody, TKI – Tyrosine kinase 
inhibitor, Bcr-Abl – Breakpoint cluster region-Abelson murine leukaemia, EGFR – Epidermal Growth 
Factor Receptor 
 
Agent Target(s) Cancer Type 
Axitinib VEGFR-1, -2, -3 Metastatic renal cancer 
Cabozantinib VEGFR-2 
RET 
Medullary thyroid cancer 
Advanced renal cell cancer 
Lenvatinib 
 





Metastatic thyroid cancer 
Renal cell cancer 
 





Metastatic Non-small cell lung cancer 




Advanced renal cell carcinoma  
Advanced soft tissue sarcoma 





Metastatic colorectal cancer 







Gastrointestinal stromal tumour (GIST) 
Advanced renal cell carcinoma   








Advanced renal cell carcinoma 
 
Tivozinib VEGFR-1, -2, -3 Advanced renal cell carcinoma 
Table 2. Categories of VEGFR TKI drugs, their tyrosine kinase targets and indications.  FGFR – 
Fibroblast Growth Factor Receptor; PDGFR – Platelet-derived Growth Factor Receptor; VEGFR – 










ACE Inhibitors /  
Angiotensin receptor 
antagonists 
Beneficial effects in patients with 
LVSD or proteinuria  
Quick onset of action 
Caution in renal impairment and 
nephrectomy 
RAA axis not substantially implicated 




Vasodilator action effective in TKI-
hypertension 
Can exacerbate fluid retention 
Slower onset of action 
Beta-blockers Beneficial effects in patients with 
LVSD 
Vasodilator action effective in TKI-
hypertension 
Contraindicated in asthma/COPD and 
decompensated HF 
Diuretics Effective in elderly patients Caution in renal impairment and 
nephrectomy 
May cause electrolyte disturbance  
Table 3. Anti-hypertensive agents for treatment of TKI-associated hypertension. The choice of anti-
hypertensive agent generally follows national guidelines for first-line treatment of hypertension and 
there is currently no clinical evidence to suggest superiority of one agent over another. Non-
dihydropyridine calcium channel blockers such as diltiazem and verapamil should be avoided as they 




Medullary thyroid cancer 
Toxicity Risk factors Investigations / Screening Management 
Hypertension Age (>65) 
Pre-existing hypertension 
Pre-existing vascular disease  
(stroke / MI / PVD) 
Diabetes Mellitus 
Monitor weekly during first cycle 
2- to 3- weekly thereafter 
Home blood pressure monitoring 
where possible 
Control existing hypertension 
ACE inhibitor / ARB 
Dihydropyridine calcium channel blocker 
Beta blocker 
Diuretics 
Dose reduction / discontinuation of TKI with severe 
hypertension 
NOT verapamil or diltiazem 




Valvular heart disease 
Previous anthracycline exposure 
Baseline imaging assessment  
Serial monitoring at 1 month and every 
3 months on TKI 
Role for biomarker testing not yet 
defined (Troponin / NT-proBNP) 
ACE inhibitor/ARB and beta blocker ± mineralocorticoid 
receptor antagonist in patients with heart failure 
Consider ACE inhibitor/beta blocker in asymptomatic 
LVSD 
Discontinuation of TKI with heart failure or significant 





Consider stress testing/coronary 
angiography in presence of potentially 
ischaemic symptoms at baseline 
Anti-platelet primary prevention should be avoided 
Safest shortest duration of DAPT after percutaneous 
coronary intervention should be sought 







Baseline ECG and electrolyte 
monitoring 
Serial monitoring 
Withdraw QT-prolonging drugs 
Temporary withdrawal of TKI with QTc >500ms or 
increase of >60ms 
Discontinuation of TKI with Torades de Pointes 
 
TABLE 4. Summary of risk factors, screening and investigations, and potential management options for the main cardiovascular toxicities associated with 
TKIs. ACE – Angiotensin-converting enzyme; ARB – Angiotensin receptor blocker; CAD – Coronary artery disease; DAPT – Dual anti-platelet therapy; LVEF 
– Left ventricular ejection fraction; LVSD – Left ventricular systolic dysfunction; MI – Myocardial infarction; NT-proBNP – N-terminal pro b-type natriuretic 
peptide; PVD – peripheral vascular disease. 
TKI Agent Average QT 
prolongation (ms) 
Increase in QTc 
>60ms (%) 
QTc >500ms (%) Torsades de 
pointes (%) 
Axitinib <10 N/a N/a N/a 
Cabozantinib 10-15 N/a N/a N/a 
Pazopanib N/a N/a 2 <0.3 
Sorafenib 8-13 N/a N/a N/a 
Sunitinib 9.6-15.4 1-4 0.5 <0.1 
Vandetanib  36 12-15 4.3-8 Described, % N/a 
Table 5. Incidence of QT prolongation with TKIs.  
 
 



